Neurocrine biosciences announces publication of phase 3 kinect®-4 post hoc analysis demonstrating clinically meaningful and sustained improvement in tardive dyskinesia with long-term use of ingrezza® (valbenazine) capsules

San diego , may 21, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the publication of data from a post hoc analysis of the phase 3 kinect®-4 study of ingrezza® (valbenazine) capsules in the journal of clinical psychopharmacology . the analysis assessed long-term outcomes relevant to the real-world management of tardive dyskinesia (td) and demonstrated that nearly all study participants met the threshold for clinically meaningful improvements in td symptom severity by week 48.
NBIX Ratings Summary
NBIX Quant Ranking